The Jordanian Stem Cell Company has signed a five year multi-million dollar agreement with US-based Stemedica Cell Technologies, Inc. to purchase stem cell and related technology from Stemedica's wholly-owned subsidiary, Stemedica International.

Under the agreement, Switzerland-based Stemedica International will provide their cell technology to the Jordanian firm and actively support their development and implementation of a clinical trial for burns.

Stemedica International is a developer and manufacturer of clinical grade stem cell products and is licensed by the State of California Food and Drug Branch.